Progyny

Progyny, Inc. is a fertility benefits management company. It provides fertility solutions to employers, managing IUI, in vitro fertilization (IVF), egg freezing, and other fertility treatments. It operates through one segment: fertility and pharmacy benefits solutions. It also delivers treatment services and access to the firm’s network of fertility specialist. The company was founded on April 3, 2008 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Progyny reports record growth in 2022, eyes sustained success

Progyny's exceptional performance in 2022, driven by record revenue growth and client additions, positions the company for continued success in 2023.
The company's strengths in provider network retention, strong gross margins, and strategic investments highlight its competitive advantage and growth potential.
Challenges such as tightening growth rates and margin sustainability require proactive strategies, while opportunities in market positioning and growth avenues offer promising prospects.
With a strong pipeline, focus on enhancing services, and commitment to growth, Progyny is poised to capitalize on market demand and drive further success.

Progyny reports record Q1 growth, raises 2023 guidance amid strong demand

Progyny's Q1 2023 performance reflects robust growth, operational efficiency, and a strategic focus on expanding market reach and service offerings. Despite potential challenges, the company remains optimistic about future prospects, raising guidance for 2023 and highlighting strong demand for fertility benefits.

Progyny reports record revenue and strong growth outlook for 2023

Progyny's Q2 2023 earnings call highlighted exceptional financial performance, strong operational metrics, and a positive outlook for future growth. The company's focus on quality care, cost containment, and market trends positions it well for continued success in the reproductive health industry.
With a robust PBM model, unique contracting approach, and commitment to data-driven outcomes, Progyny stands out as a leader in the sector. The expansion into menopause services and partnerships further strengthens its competitive edge and diversifies its service offerings.
While Progyny faces challenges in market penetration and operational scalability, the company's strategic strengths and growth opportunities present a promising outlook. By navigating industry challenges and leveraging emerging trends, Progyny is poised for sustained growth and innovation.

Progyny reports record Q3 earnings, eyes growth through diversification

Progyny's Q3 performance reflects robust growth, strong client relationships, and strategic expansion initiatives.
Despite challenges in Q4 and Progyny Rx contribution decline, the company is well-positioned for sustained growth.
Opportunities lie in diversifying services, addressing economic concerns, and leveraging partnerships for future expansion.
Overall, Progyny's proactive strategies and solid financial performance signal a promising outlook for continued success.

Progyny excels in 2023, eyes diversified growth in 2024

Progyny's exceptional 2023 performance and client-focused approach position it as a leader in fertility care.
While facing revenue challenges in Q1, Progyny's strategic initiatives and market opportunities offer avenues for growth.
The company's resilience in member activity and diversified revenue streams bode well for sustained success.
Progyny's expansion plans and competitive wins underscore its strong market position and growth potential.

Progyny reports strong Q1 performance, eyes growth opportunities ahead

Progyny's Q1 showed strength but faced challenges in utilization and revenue.
The company's business model demonstrated leverage and solid financial performance.
Opportunities lie in market trends, expanding services, and employer conversations.
Guidance for Q2 and full-year adjusted EBITDA indicates growth trajectory.
Progyny's focus on women's health and family building positions it for future success.

Progyny reports 9% revenue growth in Q2 2024 earnings call

Progyny delivered solid financial performance in Q2 2024, with revenue and gross profit showing healthy growth rates.
Despite challenges in forecasting and membership growth, the company's operational strengths and cash flow generation are notable.
Adjustments to revenue guidance reflect proactive management in response to market dynamics, while opportunities for growth and efficiency improvements are evident.
Overall, Progyny's Q2 performance highlights resilience and strategic focus amidst evolving market conditions.

Progyny reports mixed Q3 performance, focuses on client growth

Progyny faced challenges in member activity and gross margin in Q3 2024.
Despite this, positive selling season results and strong client commitments were noted.
Renewals and upsell activities remained robust, supporting revenue guidance.
The company's focus on care management services and cash flow stability is evident.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Progyny: A Growth Stock With A Unique Value Proposition

Bill.com

Datadog

Dynatrace Inc

Here are five recent IPOs near buy points: XP, Dynatrace, Progyny, Datadog and Bill.com. Three are already turning profits.

IPO Stocks XP, Dynatrace, Progyny, Datadog, Bill.com Are Near Buy Points

Zoom Video

Progyny and Zoom Video stocks are zooming.

The 2 Best-Performing Tech IPOs of 2019

Progyny (NASDAQ: PGNY), is a benefits management company that specializes in fertility and family building benefits solutions. The company’s stock is up 90% since its listing in late October, currently trading at over $30 per share.

Why Has Progyny Stock Rallied 90% Since Its Listing?

 Luckin Coffee

Ping Identity Holding Corp

IPO stocks Dynatrace, Datadog, Progyny, Ping Identity and Starbucks rival Luckin Coffee are all near buy points. But handle IPOs with care.

Hot IPO Stocks Luckin Coffee, Dynatrace, Progyny, Datadog, Ping Identity Near Buy Points

This new IPO beat earnings in its first report.

Why Progyny Stock Popped 12.5% Today

Progyny, Inc. (PGNY) CEO David Schlanger on Q3 2019 Results - Earnings Call Transcript

Fertility benefits manager and recent IPO Progyny reports third-quarter earnings after the close as the stock sets up in a base.

This Hot IPO Should Report A Profit In First Report As Stock Nears Buy Point

Salesforce

Dollar General

Salesforce.com, Dollar General, Marvell Technology, Synopsys and hot IPO Progyny are near buy points with earnings on tap. 
The post Salesforce, Dollar General, Progyny Lead 5 Stocks Near Buys With Earnings Due appeared first on Investor's Business Daily.

Salesforce, Dollar General, Progyny Lead 5 Stocks Near Buys With Earnings Due

New York, Nov.  26, 2019  (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced its participation in two upcoming investor conferences.

Update: Progyny, Inc. Announces Participation in Upcoming Investor Conferences

Progyny, Inc. Announces Participation in Upcoming Investor Conference[s]

Bellerophon Therapeutics

Comcast

OPKO Health

StoneMor Partners

According to these filters, the following are significant trades from company insiders this month.

Largest Insider Trades of the Week (Nov 01)

Progyny Inc.: Great Business, Absurd Valuation

NEW YORK, Oct.  29, 2019  (GLOBE NEWSWIRE) -- Progyny, Inc., a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced the closing of its initial public offering of 11,500,000 shares of its common stock, including the full exercise by the underwriters of their option to purchase 1,500,000 additional shares of common stock, at a price to the public of $13.00 per share. Progyny offered and sold 6,700,000 shares and the selling stockholders offered and sold 4,800,000 shares. Progyny’s shares of common stock are listed for trading on the Nasdaq Global Select Market under the ticker symbol “PGNY.”

Progyny, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Progyny Inc., the fertility and family building benefits company that serves US employers like Google, Apple, announced its Initial Public Offering of 10,000,000 shares at a price of $13.00 per share, becoming the first fertility benefits company to ever go public.

Fertility Company Progyny Joins NASDAQ With Initial Public Offering At $13 Per Share

Fertility Company Progyny Goes Public; Joins NASDAQ With Initial Public Offering At $13 Per Share

News for Progyny Stock (PGNY)